PDS Biotechnology Corporation has announced positive clinical and translational data for its investigational HPV16-targeted immunotherapy PDS0101 and its novel immunocytokine PDS01ADC. The results were presented at the 2025 Society for Immunotherapy of Cancer $(SITC)$ Annual Meeting, including one rapid oral abstract and two poster presentations. The studies, conducted in collaboration with the National Cancer Institute $(NCI)$ Center for Cancer Research, demonstrated that multiple immunological biomarkers can predict the clinical activity of PDS0101 in combination therapy. Additionally, PDS01ADC was shown to reprogram natural killer cells to enhance their cancer-killing activity and promote stem cell-like and memory T cells with long-lasting anti-tumor potential. PDS Biotech is advancing PDS01ADC through NCI-led Phase 2 clinical trials in several cancer types, including metastatic colorectal cancer, cholangiocarcinoma, and prostate cancer.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. PDS Biotechnology Corporation published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001140361-25-041286), on November 10, 2025, and is solely responsible for the information contained therein.
Comments